Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


GREY:BIOAF - Post by User

Comment by Boomskidon Feb 27, 2023 9:01pm
84 Views
Post# 35308555

RE:$.02

RE:$.02I forgot. Bioasis is not at 1.5¢ today. Bioasis was up 33.3% today, from 1.5¢ to 2¢.

Does Bioasis still have a deal with Prothena? My guess? Yes, but I doubt any work is being done. It will be 5 years this year since the Prothena deal was announced. Not too likely that Prothena is still in the pab with that, if it ever was.

Why is xB3-001 still absent from the list, poof? Has Bioasis sold it? I mean, we did more work with xB3-001 than any other internal program and now it's missing. We had an FDA reponse to a pre-IND submission - and it's not a part of Bioasis anymore? 

Does Bioasis still owe money to WuXi for xB3-001? I wonder if Bioasis is hiding xB3-001 from WuXi? ("No. WuXi, we've only shelved it. There are no deals for it. If we have anything, we'll let you know, although we'll need an NDA so that you won't let shareholders know about it.")

Has WuXi placed a lien on xB3-001 preventing its advancement? Has somebody else paid Bioasis's WuXi debts? Has xB3-001 been betrothed to another? Or is xB3-001 just lying there, on the shelf, waiting for another lover, or a first one?)

I wonder how many sufferers of brain tumours believe the Tweet about BioasisUS and rare diseases?

What has been the cost in shareholder value and rare disease deaths that could have been different, if only Bioasis had...

jd
<< Previous
Bullboard Posts
Next >>